Monopar Therapeutics Inc. has appointed Susan Rodriguez as its new Chief Commercial and Strategy Officer, effective immediately. This newly created executive role is crucial as Monopar prepares for the planned submission of a New Drug Application (NDA) to the U.S. FDA in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson disease. Ms. Rodriguez will be responsible for leading the company's commercial strategy and building out the necessary infrastructure. She brings over 30 years of biopharmaceutical leadership experience, including previous roles as Chief Operating Officer of Avadel Pharmaceuticals and Chief Commercial Officer of Ardelyx. Her experience includes successfully launching innovative rare disease therapies and transitioning development-stage companies to commercial enterprises.